Results 151 to 160 of about 25,910 (264)

PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy

Advanced Science, Volume 13, Issue 61, 3 November 2026.
A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu, Qiang Chen, Zhe Zhou, Yuekang Xu, Jinyao Li   +4 more
wiley   +1 more source

Selective expansion of neoantigen-specific peripheral blood lymphocytes through antigen-presenting cell-T cell conjugate isolation. [PDF]

J Immunother Cancer
Khateb M, Jung R, Hadley P, Leibou S, Yu Z, Dinerman AJ, Dulemba V, Gasmi B, Levin N, Kim SP, Bhasin A, Bhat D, Sindiri S, Gartner JJ, Prickett TD, Benzine T, Farid S, Parkhurst M, Halas H, Ge G, Cao Y, Zhao K, Yang JC, Robbins P, Lowery FJ, Krishna S, Heller T, Mcvicar D, Rosenberg SA, Klemen ND.   +29 more
europepmc   +1 more source

Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An, Junfeng Zhao, Wenjie Chen, Ying Li, Yifei Yan, Chen Zhou, Ruyue Li, Xiujing Yao, Xue Dong, Xingying Yang, Yongjuan Hu, Jiaxuan Chen, Chuankun Han, Yingrui Bai, Yali Xu, Yintao Li   +15 more
wiley   +1 more source

Evaluation of Computational Neoantigen Prioritization Strategies for Personalized Cancer Vaccines. [PDF]

Vaccines (Basel)
Zyrin V, Mozheiko E, Valiev I, Lazarev A, Gevorkyan T, Murashko M, Okonechnikov K.   +6 more
europepmc   +1 more source

Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID‐19

Clinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Drug‐induced thrombocytopenia is a condition where certain medications can significantly reduce the platelets in the blood. This can increase the risk of bleeding and bruising. We reported a case of a 73‐year‐old woman with multiple comorbidities who was admitted to the hospital with COVID‐19.
Abdullah F. Alharthi, Munirah A. Alkathiri, Othman Alomeir, Shmeylan Al Harbi, Ohoud Aljuhani, Haifa A. Alhaidal, Khalid Al Sulaiman   +6 more
wiley   +1 more source

The microbiome and brain metastasis in non‐small cell lung cancer: A graded appraisal and a framework for prevention‐oriented research

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
This Review proposes a microbiome–premetastatic brain niche axis connecting gut, lung, and intratumoral microbes with metabolites, blood–brain barrier remodeling, neuroimmune priming, and brain metastasis in NSCLC. It integrates current evidence while distinguishing established mechanisms from associations and hypotheses requiring prospective and ...
Long Liang, Fangjuan Hu, Xiaofeng Wang, Chunhan Tang, Chun Wang, Gefei Jiang, Chungang Zhao, Yin Zhang, Churong Li   +8 more
wiley   +1 more source

Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade. [PDF]

Int J Mol Sci
Demircan T, Yıldırım B, Ünsal Hİ, Bilir A.   +3 more
europepmc   +1 more source

Randomized Phase II Trial of Consolidation Pembrolizumab After Definitive Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: KCSG HN19‐09, CONPELAN Study

Head &Neck, Volume 48, Issue 11, Page 3103-3112, November 2026.
ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun, Seyoung Seo, Jang Ho Cho, Keon‐Uk Park, Sang‐Cheol Lee, Yong Won Choi, Tak Yun, Seong Hoon Shin, Sung‐Bae Kim, Seungeun Lee, Chang Ho Ahn, Bhumsuk Keam   +11 more
wiley   +1 more source

Low tumor burden follicular lymphoma: The state of the art

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract Follicular lymphoma (FL) is the commonest indolent non‐Hodgkin lymphoma. Most patients present with advanced‐stage and are stratified by the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria into high or low tumor burden (LTB). Randomized trials in LTB FL demonstrated no overall survival advantage with immediate treatment compared to ...
Greg Hapgood, Joshua Tobin, Robert Kridel, Brad Kahl   +3 more
wiley   +1 more source

Recent Advances in Lipid Nanoparticles for Cancer Vaccines: From Antigen Delivery to Personalized Immunotherapy. [PDF]

Int J Mol Sci
Rachamala HK, Angom RS, Marepally S.
europepmc   +1 more source